IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Table 1

Characteristics of the patients and their clinical parameters (mean ± SD).

Patients, mean age ± SD: 41.1 ± 11.3
Males	77
Females	51
HCV genotypes
1b	82
3a	46
Fibrosis stages
F0	56
F1	26
F2	19
F3	7
F4	20
Portal inflammation
Scores S3–4 (moderate and marked inflammation in all portal areas)	51
Scores S0–2 (without inflammation or with mild and moderate inflammation in some or all portal areas)	68
Response to Peg-IFN/RBV treatment
SVR	69
NR	18
	22
Clinical parameters	Mean ± SD
Viral load, IU × 10^6/mL	1.81 ± 2.01
Anti-HCV Abs, S/CO	93.5 ± 37.8
Aspartate aminotransferase (AST), IU/L	71.4 ± 77.1
Alanine aminotransferase (ALT), IU/L	103.1 ± 93.3
AST/ALT ratio	0.81 ± 0.78
AST/PLT ratio	0.37 ± 0.43
Bilirubin, μmol/L	12.5 ± 5.9
Gamma-glutamyltransferase, IU/L	73.4 ± 78.9
Alkaline phosphatase (ALP), IU/L	80.0 ± 32.4
Ferritin, μg/L	155.5 ± 138.3
Thyroid-stimulating hormone, mIU/L	1.41 ± 0.86
Alpha-fetoprotein (AFP), μg/L	2.89 ± 1.81